Alnylam Pharmaceuticals (NASDAQ: ALNY)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Alnylam Pharmaceuticals Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Alnylam Pharmaceuticals Company Info
A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.
News & Analysis
These three biotech companies could be headed for a buyout soon.
It's pursuing a smart and tightly focused drug development strategy that could pay off big.
The RNAi drugmaker hits the mark in a rare form of heart failure.
After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences.
This could be a very exciting year for these drugmakers.
The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.
The company's earnings fell short of expectations and its CEO is leaving.
Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.
ALNY earnings call for the period ending September 30, 2021.
ALNY earnings call for the period ending June 30, 2021.
ALNY earnings call for the period ending March 31, 2021.
ALNY earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.